A Study on Correlation of COVID-19 Vaccination and Hospitalization among Adults Aged 45 Years and Above: A Hospital Based Case Control Study
Keywords:
Covid-19, Vaccination, Antibody, HospitalizationAbstract
Introduction: Year 2020 witness emergence of a pandemic caused by a novel severe acute respiratory syndrome – coronavirus 2 (SARS-CoV-2). After the availability of the vaccine, it is important to assess its effectiveness in reducing morbidity and mortality. The study was conducted to determine the effectiveness of vaccination against severe COVID-19 disease among individuals aged 45 years and above
Methodology: The study included patients hospitalized in selected tertiary care hospital and individuals attending SARS-CoV-2 testing facility in the hospital. It was case–control study. Covid19 RTPCR positive cases admitted in hospital were taken as cases and individuals attending the COVID-19 testing facility of hospitals diagnosed negative for SARS-CoV-2 by rRT-PCR were taken as control. The study was done in second quarter of the year 2021.
Results: The vaccination was significantly high among controls (63.5%) in comparison to cases (14.5%). This indicates that vaccination has significantly reduces hospitalization. The vaccination has very positive effect in reducing hospitalization (OR 0.1 (0.05-0.2)).
Conclusion: Vaccine was very effective in reducing hospitalization due to Covid19. So, this study strongly support vaccination in above 45-year age people.
References
Government of India. COVID-19 Dashboard. https://www. mygov.in/covid-19
Draft landscape and tracker of COVID-19 candidate vaccines. Geneva: World Health Organization; 2021 (https://www. who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines, accessed 19 April 2021).
Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021 Jan 9;397(10269):99-111.
AZD1222 US Phase III primary analysis confirms safety and efficacy. AstraZeneca: 25 March 2021. https://www.astra zeneca.com/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html
Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of COVAXIN®. Hyderabad: Bharat Biotech: 21 April 2021. https://www.bharatbiotech.com/images/ press/ covaxin-phase3-clinical-trials-interim-results.pdf
Ministry of Health and Family Welfare. Frequently Asked Questions – COVID vaccination. Government of India. https:// www.mohfw.gov.in/covid_vaccination/vaccination/faqs.html#who-will-get-the-vaccine
World Health Organization. Evaluation of COVID-19 vaccine effectiveness - Interim Guidance, 17 March 2021. Geneva: WHO 2021
Clinical management of COVID-19: interim guidance. Geneva: World Health Organization; 2020 (https://www.who.int/ publications/i/item/clinical-management-of-covid-19, accessed 22 April 2021).
World Health Organization. Maintaining surveillance of influenza and monitoring SARS-CoV-2 – adapting Global Influenza surveillance and Response System (GISRS) and sentinel systems during the COVID-19 pandemic [Internet]. [cited 2021 April 22]. Available from: https://www.who.int/publications-detail-redirect/
O’Neill RT. On sample sizes to estimate the protective efficacy of a vaccine. Stat Med. 1988;7:1279-88. doi: 10.1002/ sim.4780071208.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright of their article, with first publication rights granted to Medsci Publications.
